 zidovudine interferon-alpha treatment patients AIDS-associated Kaposi sarcoma effectiveness addition interferon-alpha IFN-alpha patients AIDS-associated Kaposi sarcoma non-randomized phase II clinical trial patients oral zidovudine mg IFN-alpha MU weeks evaluable patients partial response weeks months IFN-alpha dose escalation patients responses myelotoxicity mild fatigue dose-limiting side-effect dose escalation eligible patients combined treatment decrease HIV-Ag summary results addition IFN-alpha patients AIDS-associated Kaposi sarcoma efficacious treatment